Testing an AI chat system for collecting medical history in depression care
Compares an AI chat intake tool with usual care for adults with depression.
Plain-language title generated from the registry record
Registry title: Evaluating Conversational Artificial Intelligence for Depression Management
Key facts
- Where
- Fairfax, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT07105397, who can take part
Where in United States
- George Mason UniversityFairfax, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- George Mason University
- Trial code
- NCT07105397
- Record updated
- 9 September 2026
- Original description
The goal of this clinical trial is to evaluate how a conversational method of collecting medical history affects patients' perceptions and experiences compared to clinical care as usual. This conversational AI intake system collects medical history information, can be completed by participants at home, and do not disrupt routine clinical care.Read full original descriptionShow less
Evaluating Conversational Artificial Intelligence for Depression Management
The goal of this clinical trial is to evaluate how a conversational method of collecting medical history affects patients' perceptions and experiences compared to clinical care as usual. This conversational AI intake system collects medical history information, can be completed by participants at home, and do not disrupt routine clinical care.
The primary questions this study aims to answer are:
1) Does conversational intake affect patients' perceptions of empathy during their clinical interactions?
This will be a prospective study that follows a cohort of participants for four (4) months after engaging with the AI intake system. Because each participant serves as his/her own control, both comparators will be administered within-subject, and the order of exposure (AI intake vs. usual care) will be randomized to minimize sequence effects.
After completing the AI intake method, participants will rate their experience, particularly in terms of empathy and compare it to their usual interactions with their own clinicians.
Participant is between 18 to 85 years old; Participant has been, or are likely to be, diagnosed with moderate to severe Major Depressive Disorder without signs of bipolar depression; Participant is not in active suicidal crisis and do not face imminent risk of suicide within the next 3 hours; Participant is not pregnant or seeking to be pregnant; Participant able to communicate in English on the Internet; Participant must reside in the United States; Participant has access to a mental health clinician, or the participant is willing to see study clinicians to help review the advice and medication adjustments recommended by the AI Intake System to the participant; If the participant is seeing study clinicians, the participant must reside in a state where study clinicians are licensed; Participant must be using a device (phone or computer) that is located in the United States.